(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 April 2011 (07.04.2011)

PCT

(10) International Publication Number
WO 2011/039721 A1

(51) International Patent Classification:
C07D 498/18 (2006.01) *C07K 16/46* (2006.01)
A61K 31/537 (2006.01) *C07K 16/30* (2006.01)
A61P 35/00 (2006.01) *C12P 21/08* (2006.01)

(21) International Application Number:
PCT/IB2010/054417

(22) International Filing Date:
30 September 2010 (30.09.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09305939.2 2 October 2009 (02.10.2009) EP

(71) Applicant *(for all designated States except US)*: **SANOFI-AVENTIS** [FR/FR]; 174 avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BOUCHARD, Hervé** [FR/FR]; c/o Sanofi-Aventis Département Brevets, 174 avenue de France, F-75013 Paris (FR). **COMMERCON, Alain** [FR/FR]; c/o Sanofi-Aventis Département Brevets, 174 avenue de France, F-75013 Paris (FR). **FROMOND, Claudia** [FR/FR]; c/o Sanofi-Aventis Département Brevets, 174 avenue de France, F-75013 Paris (FR). **MIKOL, Vincent** [FR/FR]; c/o Sanofi-Aventis Département Brevets, 174 avenue de France, F-75013 Paris (FR). **PARKER, Fabienne** [FR/FR]; c/o Sanofi-Aventis Département Brevets, 174 avenue de France, F-75013 Paris (FR). **SASSOON, Ingrid** [FR/FR]; c/o Sanofi-Aventis Département Brevets, 174 avenue de France, F-75013 Paris (FR). **TAVARES, Daniel** [US/US]; c/o ImmunoGen Inc., 830 Winter Street, Waltham, Massachusetts 02451 (US).

(74) Agent: **SENNINGER, Thierry**; c/o Sanofi-Aventis, Patent Department, 174 avenue de France, F-75013 Paris (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: NEW MAYTANSINOIDS AND THE USE OF SAID MAYTANSINOIDS TO PREPARE CONJUGATES WITH AN ANTIBODY



(I)

(57) Abstract: The invention relates to a compound of formula (I): wherein : • ALK is a (C_1-C_6)alkylene group; • X_1 et X_2 are each independently one of the following groups : -CH=CH-, -CO-, -CONR-, - NRCO-. -COO-. -OCO-. -OCONR-. -NRCOO-. -NRCONR'-. -NR-. -S(O)$_n$ (n=0,1 or 2) or O-; • R and R' are independently H or a (C_1-C_6)alkyl group; • I is an integer of from 1 to 40, preferably from 1 to 20, and more preferably from 1 to 10; • j is an integer corresponding to 1 when X_2 is -CH=CH- and 2 when X_2 is not -CH=CH-; • Z_b is a simple bond, -O- or -NH- and R_b is H or a (C_1-C_6)alkyl, (C_3-C_7)cycloalkyl, aryl, heteroaryl or (C_3-C_7)heterocycloalkyl group; or Z_b is a single bond and R_b is Hal. The invention relates to the use of said maytansinoids to prepare conjugates with an antibody having an affinity for tumor cells.

WO 2011/039721 A1